Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
4.250
+0.040 (0.95%)
At close: Jun 26, 2026, 4:00 PM EDT
4.240
-0.010 (-0.24%)
After-hours: Jun 26, 2026, 7:57 PM EDT

Iovance Biotherapeutics Stock Forecast

Stock Price Forecast

According to 10 analysts polled by S&P Global, Iovance Biotherapeutics stock has a consensus rating of "Buy" and an average price target of $8.80. The average 1-year stock price forecast is 107.06% higher than the current stock price, while the lowest is $4.00 (-5.88%) and the highest is $14 (+229.41%).

Price Target: $8.80 (+107.06%)
Analyst Consensus: Buy
TargetLowAverageMedianHigh
Price$4.00$8.80$9.50$14
Change-5.88%+107.06%+123.53%+229.41%

Analyst Ratings

The average analyst rating for Iovance Biotherapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

RatingJan '26Feb '26Mar '26Apr '26May '26Jun '26
Strong Buy666666
Buy122222
Hold433322
Sell000000
Strong Sell100000
Total121111111010

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Unknown Analyst
Mizuho Securities
No rating
Mizuho Securities
Buy
Maintains
$10
BuyMaintains$10+135.29%Jun 22, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$9
BuyReiterates$9+111.76%Jun 4, 2026
Barclays
Barclays
Buy
Maintains
$11
BuyMaintains$11+158.82%Jun 2, 2026
Chardan Capital
Chardan Capital
Buy
Reiterates
$14
BuyReiterates$14+229.41%May 8, 2026
TD Cowen
TD Cowen
Buy
Maintains
$5
BuyMaintains$5+17.65%May 7, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
361.99M
from 263.50M
Increased by 37.38%
Revenue Next Year
496.28M
from 361.99M
Increased by 37.10%
EPS This Year
-0.56
from -1.09
EPS Next Year
-0.32
from -0.56
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
--1.19M164.07M263.50M361.99M
Revenue Growth
---13,698.99%60.60%37.38%
Gross Profit
--156.00K70.82M90.32M184.35M
Gross Margin
--13.12%43.17%34.28%50.93%
Operating Income
-342.70M-398.88M-460.56M-395.28M-398.21M-246.02M
Net Income
-342.25M-395.89M-444.04M-372.18M-390.98M-239.09M
EPS
-----1.09-0.56
Free Cash Flow
-129.35M-173.54M-211.47M-198.76M-162.42M-213.00M
No. Analysts
-----9
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High369.8M
Avg362.0M
Low352.0M

Revenue Growth

Revenue Growth202620272028
High
40.3%
Avg
37.4%
Low
33.6%

EPS Forecast

EPS202620272028
High-0.46
Avg-0.56
Low-0.72

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-